TN2015000106A1 - 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors - Google Patents

5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors

Info

Publication number
TN2015000106A1
TN2015000106A1 TNP2015000106A TN2015000106A TN2015000106A1 TN 2015000106 A1 TN2015000106 A1 TN 2015000106A1 TN P2015000106 A TNP2015000106 A TN P2015000106A TN 2015000106 A TN2015000106 A TN 2015000106A TN 2015000106 A1 TN2015000106 A1 TN 2015000106A1
Authority
TN
Tunisia
Prior art keywords
reverse transcriptase
hiv reverse
transcriptase inhibitors
pyrimidin
phenoxy
Prior art date
Application number
TNP2015000106A
Other languages
English (en)
Inventor
Kenneth L Arrington
Christopher Burgey
Robert Gilfillan
Yongxin Han
Mehul Patel
Chun Sing Li
Yaozong Li
Yunfu Luo
Jiayi Xu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TN2015000106A1 publication Critical patent/TN2015000106A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
TNP2015000106A 2012-10-08 2015-03-23 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors TN2015000106A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012001358 2012-10-08
PCT/US2013/063612 WO2014058747A1 (fr) 2012-10-08 2013-10-07 Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih

Publications (1)

Publication Number Publication Date
TN2015000106A1 true TN2015000106A1 (en) 2016-06-29

Family

ID=49354986

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000106A TN2015000106A1 (en) 2012-10-08 2015-03-23 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors

Country Status (47)

Country Link
US (3) US9469634B2 (fr)
EP (3) EP2903977B1 (fr)
JP (2) JP5877281B2 (fr)
KR (1) KR101696128B1 (fr)
CN (1) CN104822670B (fr)
AP (1) AP2015008355A0 (fr)
AR (1) AR092876A1 (fr)
AU (1) AU2013329552B8 (fr)
BR (1) BR112015007742B8 (fr)
CA (1) CA2887312C (fr)
CL (1) CL2015000880A1 (fr)
CO (1) CO7350655A2 (fr)
CR (1) CR20150183A (fr)
CY (3) CY1119655T1 (fr)
DK (3) DK3656384T3 (fr)
DO (1) DOP2015000082A (fr)
EA (1) EA033436B1 (fr)
EC (1) ECSP15018618A (fr)
ES (3) ES2770774T3 (fr)
GE (1) GEP20186838B (fr)
GT (1) GT201500088A (fr)
HK (2) HK1207369A1 (fr)
HR (3) HRP20220502T1 (fr)
HU (3) HUE037231T2 (fr)
IL (1) IL238090B (fr)
JO (1) JO3470B1 (fr)
LT (3) LT3656384T (fr)
MA (1) MA37959A2 (fr)
MD (1) MD4625C1 (fr)
ME (1) ME02918B (fr)
MX (1) MX355040B (fr)
MY (1) MY192716A (fr)
NI (1) NI201500048A (fr)
NO (1) NO2903977T3 (fr)
NZ (1) NZ706729A (fr)
PE (1) PE20151787A1 (fr)
PH (1) PH12015500764A1 (fr)
PL (3) PL3295942T3 (fr)
PT (3) PT2903977T (fr)
RS (3) RS59863B1 (fr)
SG (1) SG11201502620UA (fr)
SI (3) SI3295942T1 (fr)
TN (1) TN2015000106A1 (fr)
TW (2) TWI538907B (fr)
UA (1) UA114006C2 (fr)
WO (1) WO2014058747A1 (fr)
ZA (1) ZA201503143B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
WO2015036563A1 (fr) 2013-09-16 2015-03-19 Bayer Pharma Aktiengesellschaft Trifluorométhylpyrimidones disubstituées et leur utilisation comme antagonistes du ccr2
KR102440843B1 (ko) * 2014-04-01 2022-09-29 머크 샤프 앤드 돔 엘엘씨 Hiv 역전사효소 억제제의 전구약물
CA2959208C (fr) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Derives de pyrimidine et utilisation comme inhibiteurs de .alpha.-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
WO2017070632A2 (fr) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Éditeurs de nucléobases et leurs utilisations
CA3032699A1 (fr) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Editeurs de nucleobases d'adenosine et utilisations associees
WO2018031683A1 (fr) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Protéines de fusion cas9-recombinase programmables et utilisations associées
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
EP3526320A1 (fr) 2016-10-14 2019-08-21 President and Fellows of Harvard College Administration d'aav d'éditeurs de nucléobases
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (fr) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression de la douleur par édition de gène
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
KR102687373B1 (ko) 2017-03-23 2024-07-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
WO2018209320A1 (fr) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Arn guides incorporés par aptazyme pour une utilisation avec crispr-cas9 dans l'édition du génome et l'activation transcriptionnelle
EP3658573A1 (fr) 2017-07-28 2020-06-03 President and Fellows of Harvard College Procédés et compositions pour l'évolution d'éditeurs de bases à l'aide d'une évolution continue assistée par phage (pace)
WO2019139645A2 (fr) 2017-08-30 2019-07-18 President And Fellows Of Harvard College Éditeurs de bases à haut rendement comprenant une gam
US20230203028A1 (en) * 2017-09-18 2023-06-29 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
CA3090652A1 (fr) 2018-02-06 2019-08-15 The General Hospital Corporation Arn a motifs repetes utilises comme biomarqueurs de reponse immunitaire tumorale
IL278116B2 (en) 2018-04-30 2024-04-01 Ribon Therapeutics Inc Pyridazines as PAR7 inhibitors
EP4414365A1 (fr) 2018-09-18 2024-08-14 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
JOP20210149A1 (ar) * 2018-12-18 2023-01-30 Merck Sharp & Dohme مشتقات بيريميدين تعمل كعوامل انتقائية ضد الخلايا المصابة بفيروس نقص المناعة البشرية
WO2020191249A1 (fr) 2019-03-19 2020-09-24 The Broad Institute, Inc. Procédés et compositions pour l'édition de séquences nucléotidiques
MX2021014247A (es) * 2019-05-22 2022-01-06 Merck Sharp & Dohme Llc Derivados piridinona como agentes citotoxicos selectivos contra celulas infectadas con virus de inmunodeficiencia humana (vih).
US20240091303A1 (en) * 2019-10-04 2024-03-21 Goldfinch Bio, Inc. Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
KR20220109401A (ko) 2019-10-30 2022-08-04 리본 테라퓨틱스 인코포레이티드 Parp7 억제제로서의 피리다진온
JPWO2021107066A1 (fr) 2019-11-28 2021-06-03
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
MX2022014008A (es) 2020-05-08 2023-02-09 Broad Inst Inc Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
JP2023543803A (ja) 2020-09-24 2023-10-18 ザ ブロード インスティテュート，インコーポレーテッド プライム編集ガイドｒｎａ、その組成物、及びその使用方法
CA3203876A1 (fr) 2021-01-11 2022-07-14 David R. Liu Variants d'editeur primaire, constructions et procedes pour ameliorer l'efficacite et la precision d'une edition primaire
EP4363418A1 (fr) * 2021-07-01 2024-05-08 JANSSEN Pharmaceutica NV Acétamides 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl
JP2024530487A (ja) 2021-08-06 2024-08-21 ザ ブロード インスティテュート，インコーポレーテッド 改善されたプライムエディターおよび使用方法
WO2023076898A1 (fr) 2021-10-25 2023-05-04 The Broad Institute, Inc. Procédés et compositions pour l'édition d'un génome à l'aide d'une édition primaire et d'une recombinase
GB202409668D0 (en) 2021-12-03 2024-08-14 Broad Inst Inc Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (fr) 2022-04-20 2023-10-26 The Broad Institute, Inc. Procédés et compositions d'édition primaire améliorés
WO2023240137A1 (fr) 2022-06-08 2023-12-14 The Board Institute, Inc. Variants de cas14a1 évolués, compositions et méthodes de fabrication et d'utilisation de ceux-ci dans l'édition génomique
WO2024077267A1 (fr) 2022-10-07 2024-04-11 The Broad Institute, Inc. Méthodes et compositions d'édition d'amorce pour traiter des troubles de répétition de triplet
WO2024108092A1 (fr) 2022-11-17 2024-05-23 The Broad Institute, Inc. Distribution d'éditeur primaire par vaa
WO2024168147A2 (fr) 2023-02-09 2024-08-15 The Broad Institute, Inc. Recombinases évoluées pour éditer un génome en combinaison avec une édition primaire

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
MXPA00010490A (es) 1998-04-27 2002-10-17 Ct Nat De La Rech S Scient Derivados 3-(amino-o-aminoalquil) piridinona y su uso para el tratamiento de enfermedades relacionadas con el vih.
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
CA2518823A1 (fr) 2003-03-24 2004-10-07 F.Hoffmann-La Roche Ag Benzyl-pyridazinones en tant qu'inhibiteurs de transcriptase inverse
WO2005070901A2 (fr) 2004-01-12 2005-08-04 Gilead Sciences, Inc. Composes antiviraux de phosphonate de pyrimidyle et procedes d'utilisation
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
CA2563180C (fr) 2004-04-23 2013-08-06 F. Hoffmann-La Roche Ag Inhibiteurs de la transcriptase inverse non nucleosidiques
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
EP1940782B1 (fr) 2005-10-19 2009-03-11 F.Hoffmann-La Roche Ag N-phénylphénylacétamides en tant qu'inhibiteurs de transcriptases inverses non-nucléosides
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
US20080207654A1 (en) 2006-11-24 2008-08-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
US8404856B2 (en) * 2007-11-20 2013-03-26 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
US8686141B2 (en) * 2008-01-08 2014-04-01 Merck Sharp & Dohme Corp. Process for preparing N-substituted hydroxypyrimidinone carboxamides
MX2012011379A (es) 2010-03-30 2012-11-30 Merck Canada Inc Inhibidores no nucleosidicos de la transcriptasa inversa.
WO2011126969A1 (fr) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Promédicaments d'un inhibiteur de la transcriptase inverse du vih
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
KR102440843B1 (ko) 2014-04-01 2022-09-29 머크 샤프 앤드 돔 엘엘씨 Hiv 역전사효소 억제제의 전구약물

Also Published As

Publication number Publication date
ES2770774T3 (es) 2020-07-03
SI3295942T1 (sl) 2020-03-31
PT2903977T (pt) 2017-11-14
MD20150047A2 (ro) 2015-08-31
CL2015000880A1 (es) 2015-08-28
SI2903977T1 (sl) 2017-12-29
EA033436B1 (ru) 2019-10-31
BR112015007742B1 (pt) 2021-01-19
CN104822670A (zh) 2015-08-05
BR112015007742A2 (pt) 2017-08-08
AU2013329552C1 (en) 2016-12-22
CA2887312C (fr) 2017-02-28
EP3656384A1 (fr) 2020-05-27
US20140100231A1 (en) 2014-04-10
MX2015004448A (es) 2016-02-17
MX355040B (es) 2018-03-28
PL2903977T3 (pl) 2018-01-31
TWI538907B (zh) 2016-06-21
SG11201502620UA (en) 2015-05-28
TWI598343B (zh) 2017-09-11
GT201500088A (es) 2017-09-28
EP2903977B1 (fr) 2017-09-20
HUE037231T2 (hu) 2018-08-28
PL3295942T3 (pl) 2020-05-18
GEP20186838B (en) 2018-04-10
HRP20171819T1 (hr) 2017-12-29
HK1252786A1 (zh) 2019-05-31
RS63112B1 (sr) 2022-05-31
HRP20220502T1 (hr) 2022-05-27
SI3656384T1 (sl) 2022-05-31
EP2903977A1 (fr) 2015-08-12
CA2887312A1 (fr) 2014-04-17
LT3295942T (lt) 2020-02-10
LT3656384T (lt) 2022-05-10
MA37959A2 (fr) 2017-12-29
HRP20200158T1 (hr) 2020-08-07
MD4625C1 (ro) 2019-11-30
ES2645638T3 (es) 2017-12-07
UA114006C2 (xx) 2017-04-10
TW201420576A (zh) 2014-06-01
US9469634B2 (en) 2016-10-18
CN104822670B (zh) 2018-01-12
RS59863B1 (sr) 2020-03-31
EA201590674A1 (ru) 2016-02-29
DK3656384T3 (da) 2022-04-19
AU2013329552A1 (en) 2015-04-16
DOP2015000082A (es) 2015-08-16
DK2903977T3 (en) 2017-12-04
BR112015007742B8 (pt) 2021-03-23
LT2903977T (lt) 2017-12-11
CY1122585T1 (el) 2021-01-27
MY192716A (en) 2022-09-05
ECSP15018618A (es) 2019-06-30
JP5877281B2 (ja) 2016-03-02
ME02918B (fr) 2018-10-20
US10189831B2 (en) 2019-01-29
HUE058903T2 (hu) 2022-09-28
US20170349585A1 (en) 2017-12-07
JP2016128470A (ja) 2016-07-14
CR20150183A (es) 2015-08-10
PL3656384T3 (pl) 2022-04-04
MD4625B1 (ro) 2019-04-30
DK3295942T3 (da) 2020-02-10
NZ706729A (en) 2018-09-28
AR092876A1 (es) 2015-05-06
JP6097422B2 (ja) 2017-03-15
PT3295942T (pt) 2020-02-18
HUE048670T2 (hu) 2020-08-28
WO2014058747A1 (fr) 2014-04-17
PT3656384T (pt) 2022-03-22
ZA201503143B (en) 2016-06-29
CY1119655T1 (el) 2018-04-04
NI201500048A (es) 2016-06-29
US9718819B2 (en) 2017-08-01
EP3295942A1 (fr) 2018-03-21
EP3656384B1 (fr) 2022-02-23
TW201623256A (zh) 2016-07-01
JP2015533123A (ja) 2015-11-19
PH12015500764B1 (en) 2015-07-27
HK1207369A1 (en) 2016-01-29
IL238090B (en) 2019-02-28
PH12015500764A1 (en) 2015-07-27
PE20151787A1 (es) 2015-12-03
AU2013329552B8 (en) 2017-01-12
KR101696128B1 (ko) 2017-01-13
US20160145255A1 (en) 2016-05-26
NO2903977T3 (fr) 2018-02-17
AP2015008355A0 (en) 2015-04-30
RS56543B1 (sr) 2018-02-28
CO7350655A2 (es) 2015-08-10
ES2909190T3 (es) 2022-05-05
AU2013329552B2 (en) 2016-09-15
KR20150065186A (ko) 2015-06-12
CY1125202T1 (el) 2024-02-16
JO3470B1 (ar) 2020-07-05
EP3295942B1 (fr) 2019-11-20

Similar Documents

Publication Publication Date Title
PH12015500764A1 (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
TN2012000455A1 (en) Non-nucleoside reverse transcriptase inhibitors
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
TN2009000243A1 (en) Non-nucleoside reverse transcriptase inhibitors
WO2008054605A3 (fr) Inhibiteurs de transcriptase inverse non nucléosidique
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
EA201170537A1 (ru) Ингибиторы вич-интегразы
WO2015017393A3 (fr) Dérivés de pipérazine utilisés en tant qu'inhibiteurs de la protéase du vih
WO2011025683A8 (fr) Inhibiteurs de l'intégrase du vih
WO2007002481A3 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
TN2011000151A1 (en) Hiv integrase inhibitors
UA108495C2 (en) Reverse transcriptase nucleoside inhibitors
CY1116437T1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης